In order to identify histone signatures that are elicited by the drugs through canonical signaling pathways, we investigated the relationships between the 31 drugs targeting serine-threonine kinases in the breast cancer line (MCF7), using the resulting GCP response at 24 hours (Supplementary Table 1). The gene discussed is MARK2; the disease is breast carcinoma.